

# Lung Cancer: Non-Small Cell Lung Cancer (NSCLC) Pathways

Patient Name: \_\_\_\_\_

Date of Birth: \_\_\_\_\_

Member Number: \_\_\_\_\_

Treatment Start Date: \_\_\_\_\_

**Pathology:** \_\_\_\_\_

**Stage:** \_\_\_\_\_

**Line of Therapy:** \_\_Neoadjuvant/Pre-Op \_\_Adjuvant/Post-Op  
\_\_1<sup>st</sup> Line \_\_2<sup>nd</sup> Line \_\_3<sup>rd</sup> Line \_\_3<sup>rd</sup> Line+ \_\_Maintenance

**ECOG Performance Status:** \_\_\_\_\_ **ICD-10 Code:** \_\_\_\_\_

**Biomarkers/Characteristics:** (Select all that apply)

ALK: \_\_Positive \_\_Negative \_\_Not reported

BRAF: \_\_V600E Mutation \_\_V600K Mutation \_\_Wild type \_\_Not reported

EGFR: \_\_Mutation \_\_Wild type \_\_Not reported

PD-L1 expression: \_\_1% to 49% \_\_≥50% \_\_Negative \_\_Not reported

T790M mutation: \_\_Positive \_\_Negative \_\_Not reported

RET gene rearrangement: \_\_Absent \_\_Present \_\_Not reported

MET amplification: \_\_Positive \_\_Negative \_\_Not reported

Microsatellite instability: \_\_dMMR/MSI-H \_\_MSI-L \_\_Not reported

ROS1 rearrangement: \_\_Positive \_\_Negative \_\_Not reported

## Neoadjuvant/Preoperative/Induction Therapy or Adjuvant/Definitive Therapy

\_\_\_ Cisplatin and etoposide with concurrent XRT

\_\_\_ Paclitaxel and carboplatin with concurrent XRT

## Adjuvant Therapy

\_\_\_ Carboplatin and paclitaxel

\_\_\_ Cisplatin and gemcitabine (Gemzar)

\_\_\_ Cisplatin and vinorelbine (Navelbine)

## Metastatic Disease | Squamous | ALK/EGFR Negative (ROS Negative or Unknown) | TPS ≥ 50% | First Line of Therapy (1st Line) | ECOG PS: 0-2

\_\_\_ Pembrolizumab (Keytruda)\*

## Metastatic Disease | Squamous | TPS < 50% | First Line of Therapy (1st Line) | ECOG PS: 0-2

\_\_\_ Pembrolizumab (Keytruda), carboplatin, and paclitaxel

## Metastatic Disease | Nonsquamous | ALK/EGFR Negative (ROS1 Negative or Unknown) | TPS ≥ 50% | First Line of Therapy (1st Line) | ECOG PS: 0-2

\_\_\_ Pembrolizumab (Keytruda)\*

## Metastatic Disease | Nonsquamous | ALK/EGFR Negative (ROS1 Negative or Unknown) | TPS < 50% | First Line of Therapy (1st Line) | ECOG PS: 0-2

\_\_\_ Carboplatin†, pemetrexed (Alimta), and pembrolizumab (Keytruda)

## Metastatic Disease | Squamous or Nonsquamous | Immunotherapy-Ineligible | First Line of Therapy (1st Line) | ECOG PS: 0-2

\_\_\_ Carboplatin† and paclitaxel

\_\_\_ Carboplatin, paclitaxel, and bevacizumab (Avastin) (NON-SQUAMOUS ONLY)

\_\_\_ Cisplatin† and gemcitabine (Gemzar)

\_\_\_ Cisplatin† and pemetrexed (Alimta) (NON-SQUAMOUS ONLY)

\* Administered at a dose of 2 mg/kg (up to a maximum of 200 mg)

† In the setting of recurrent/metastatic NSCLC, a substitution of carboplatin for cisplatin (or vice-versa) will be considered a pathway option.

‡ Eligible only if immunotherapy alone was administered as first line treatment. Ineligible if chemotherapy was used in the first line setting.

**Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.**



8600 West Bryn Mawr Avenue  
South Tower - Suite 800 Chicago, IL 60631  
www.aimspecialtyhealth.com

Last review: 11/27/2018 | Effective date: 2/4/2019

Appropriate.Safe.Affordable  
© 2019 AIM Specialty Health  
9017-0219

# Lung Cancer: Non-Small Cell Lung Cancer (NSCLC) Pathways (continued)

## Metastatic Disease | Non-Squamous | Maintenance | ECOG PS: 0-2

- Continuation bevacizumab (Avastin)
- Continuation pemetrexed (Alimta)
- Pembrolizumab (Keytruda) and pemetrexed (Alimta) (if previously treated with carboplatin†, pemetrexed, and pembrolizumab)
- Switch pemetrexed (Alimta)

## Metastatic Disease | Second or Subsequent Lines of Therapy (2<sup>nd</sup> Line+) | ECOG PS: 0-2

- Atezolizumab (Tecentriq) (if no prior checkpoint inhibitors)
- Nivolumab (Opdivo) (if no prior checkpoint inhibitors)
- Carboplatin† and paclitaxel‡
- Carboplatin† and gemcitabine (Gemzar)‡
- Carboplatin† and pemetrexed (Alimta)‡

## Metastatic Disease | ALK Positive | First Line of Therapy (1<sup>st</sup> Line)

- Alectinib (Alecensa)

## Metastatic Disease | EGFR Positive | First Line of Therapy (1<sup>st</sup> Line)

- Osimertinib (Tagrisso)

## Metastatic Disease | ALK or EGFR Positive | Second or Subsequent Lines of Therapy (2<sup>nd</sup> Line+) | ECOG PS: 0-2

- Carboplatin† and paclitaxel
- Cisplatin† and gemcitabine (Gemzar)
- Cisplatin† and pemetrexed (Alimta)

## Metastatic Disease | EGFR Positive | ECOG PS: 3-4

- Erlotinib (Tarceva)

\* Administered at a dose of 2 mg/kg (up to a maximum of 200 mg)

† In the setting of recurrent/metastatic NSCLC, a substitution of carboplatin for cisplatin (or vice-versa) will be considered a pathway option.

‡ Eligible only if immunotherapy alone was administered as first line treatment. Ineligible if chemotherapy was used in the first line setting.

Note: Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.



8600 West Bryn Mawr Avenue  
South Tower - Suite 800 Chicago, IL 60631  
[www.aimspecialtyhealth.com](http://www.aimspecialtyhealth.com)

Last review: 11/27/2018 | Effective date: 2/4/2019

Appropriate.Safe.Affordable  
© 2019 AIM Specialty Health  
9017-0219